LAWRENCE, Mass., Sept. 23, 2011 /PRNewswire/ — NxStage Medical,
Inc. (Nasdaq:
NXTM), a leading manufacturer of innovative dialysis products,
today commented on the just-released findings of an NIH sponsored
study which shows that event rates, including mortality, were
significantly higher for patients following the long (2-day)
interdialytic interval associated with a three times per week
dialysis schedule (“conventional dialysis”).  The study
entitled “Long Interdialytic Interval and Mortality among Patients
Receiving Hemodialysis,” compared the rates of death and
cardiovascular-related hospital admissions on the day after the
2-day interdialytic interval with rates on other days for 32,065
in-center hemodialysis patients from the United States Renal Data
System (USRDS) database.

(Logo:
http://photos.prnewswire.com/prnh/20110503/MM94799LOGO)

Today, the large majority of dialysis patients in the US receive
conventional dialysis, which consists of treatment on a
Monday/Wednesday/Friday or Tuesday/Thursday/Saturday schedule. This
conventional in-center schedule leaves a 2-day gap between the last
treatment of the preceding week and the first treatment of the
following week, during which time toxins and fluids build up and
stress the heart and body.  

“This study’s analysis that the conventional dialysis schedule
may unnecessarily increase the risk of death for hundreds of
thousands of dialysis patients adds to the clinical evidence that
supports the benefits of a more frequent therapy paradigm.  We
believe the most cost effective place to do more frequent dialysis
is in the patient’s home with the NxStage System One,” said Jeffrey
H. Burbank, Chief Executive Officer, NxStage Medical Inc. “As we
strive to improve the health and quality of life for dialysis
patients with our life changing therapy, we look forward to working
with policy makers to ens

‘/>”/>

SOURCE